Haisco(SZ:002653) 智通财经网·2025-10-09 10:47Core Viewpoint - The company has received a notice from the National Medical Products Administration regarding the acceptance of its clinical trial application for the drug "HSK36357 capsules," which is a new small molecule drug with independent intellectual property rights developed by the company [1] Group 1: Drug Development - HSK36357 has shown significant analgesic effects in non-clinical studies and can enhance skeletal muscle contraction and improve recovery from fatigue in Duchenne Muscular Dystrophy (DMD) model mice [1] - The drug is intended for the treatment of muscular dystrophies, including Becker Muscular Dystrophy and Duchenne Muscular Dystrophy [1] - HSK36357 has already been approved for clinical trials for the indication of peripheral neuropathic pain, and the current acceptance is for the treatment of muscular dystrophies [1] Group 2: Regulatory Status - The drug is classified as a Class 1 chemical drug according to the National Medical Products Administration's regulations on chemical drug registration [1]